Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended March 31, 2025
Business Overview: NanoViricides is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral drugs using a host-mimicry nanomedicine platform. The Company operates in one reportable segment and has no commercial product revenue. Its lead candidate, NV-387, has completed Phase I safety trials and is advancing toward Phase II trials for MPox, RSV, and other viral infections.
Key Financial Metrics
| Metric | Nine Months Ended Mar 31, 2025 | Nine Months Ended Mar 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,371,085) | $(5,938,159) |
| Net Loss Per Share (Basic & Diluted) | $(0.50) | $(0.51) |
| Operating Expenses | $7,476,042 | $6,124,750 |
| Research & Development | $4,371,693 | $4,255,205 |
| General & Administrative | $3,104,349 | $1,869,545 |
| Cash Used in Operating Activities | $(6,776,773) | $(4,834,171) |
| Cash and Cash Equivalents (End of Period) | $2,542,590 | $3,257,240 |
| Total Current Liabilities | $1,198,911 | $1,358,776 |
| Stockholders' Equity | $8,833,049 | $10,651,570 |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by approximately $1.35 million (22%) compared to the prior nine-month period. This was driven primarily by a $1.23 million increase in General and Administrative expenses due to investor outreach activities and professional fees, and a $116,000 increase in R&D expenses due to outside lab fees and clinical trial costs.
- Net Loss Expansion: Net loss increased by $1.43 million year-over-year, reflecting higher operating costs partially offset by a decrease in interest income ($131,000 reduction) and a decrease in interest expense ($49,000 reduction due to the cancellation of a related-party note interest in the prior year).
- Cash Position: Cash and cash equivalents decreased by approximately $2.26 million during the period. This decline was mitigated by net proceeds of approximately $4.57 million from the sale of common stock under an At-The-Market (ATM) offering.
- Related Party Payables: Accounts payable to related parties increased to $813,477 from $720,039, largely due to the invoicing of previously accrued clinical trial costs ($237,367) from Karveer Meditech Pvt. Ltd. (KMPL).
Guidance, Outlook, and Risks
Going Concern Warning: Management has expressed substantial doubt about the Company's ability to continue as a going concern. With approximately $2.5 million in cash and a $3 million line of credit (undrawn), resources are deemed insufficient to fund planned operations for the next 12 months. The Company relies on raising additional capital through equity financing, debt, grants, or partnerships.
Clinical Outlook:
- NV-387 (MPox): Received approval from the National Ethics Committee in the Democratic Republic of Congo (DRC) to proceed with a Phase II clinical trial for MPox treatment. The Company is preparing the Clinical Trial Application (CTA).
- NV-387 (RSV): Developing Pre-IND applications for a Phase IIa trial for pediatric RSV infection.
- NV-387 (Measles): Initiated animal model studies for Measles treatment; plans to seek non-dilutive grant funding.
- COVID-19: The Phase 1a/1b clinical trial for COVID-19 was closed in April 2024 without enrolling patients due to a lack of eligible cases. The Company has paused active clinical development for this indication pending non-dilutive funding or partnerships.
Risks and Contingencies:
- Liquidity Risk: Failure to secure additional financing could force the Company to delay or curtail clinical trials.
- Related Party Dependence: The Company relies on TheraCour Pharma, Inc. (controlled by the CEO) for technology licenses and manufacturing support, and KMPL for clinical trial execution in India.
- Regulatory Uncertainty: No assurance exists that regulatory authorities will approve the Company's clinical trial applications or future drug candidates.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.5 million cash balance and the $3 million line of credit against the projected burn rate for the upcoming Phase II trials.
- Financing Plans: Assess the progress of the ATM offering and the likelihood of securing non-dilutive grants or partnership deals to fund the MPox and RSV trials.
- Related Party Transactions: Review the terms of the license agreements with TheraCour and the clinical trial agreements with KMPL to understand ongoing financial obligations and potential conflicts of interest.
- Clinical Milestones: Monitor the submission and approval status of the Phase II CTA for MPox in the DRC and the final Phase I clinical study report for NV-387.
- Intellectual Property: Confirm the status of patent applications (e.g., PCT/US21/39050) and the exclusivity of the licenses held from TheraCour.